Transcatheter Heart Valve Repair and Replacement Devices

For inquiries about purchasing this report or becoming a subscriber, please contact us at [email protected].

Globally, the epidemiology of valvular heart disease (VHD) varies substantially, with a predominance of rheumatic heart disease − the most common manifestation of VHD − in low- and middle-income countries. Global sales of transcatheter heart valve repair and replacement products were estimated at $5.9bn in 2022. Market drivers include the increasing prevalence of VHD, technological advancements, positive trial data, updated patient management guidelines, and expanded indications for transcatheter interventions. Limiters to this market include budget restrictions, lack of trained operators in some regions, high device cost, stringent regulatory approval, and procedure-associated risks and complications. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for transcatheter heart valve repair and replacement devices; these include transcatheter aortic valve replacement (TAVR) systems and transcatheter mitral valve (TMV) repair products. Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2022–27.

Related Medtech Insight articles:

• News We’re Watching: Disease X Act, Abiomed Recall, TAVR AI Cleared
• Cardio Catch-Up: Medtronic, Abbott, Ancora Devices Headline ACC, CRT, THT
• Minute Insight: Abbott Rolls Out Navitor Next-Gen TAVR System To Catch Up To Medtronic And Edwards
• Subscribe to Medtech Insight to view these articles and more!